Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity
NCT01238471Phase 2Completed
- Sponsor
- Rambam Health Care Campus
- Start
- May 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of propranolol in retinopathy of prematurity (ROP) (2 arms), sponsored by Rambam Health Care Campus. Primary endpoint: Regression of Retinopathy of Prematurity (ROP) in Premature Infants by Propranolol Therapy at 4 weeks. Started May 2010; status: completed.
02
Drugs
propranolol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT01238471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01238471.